Does FDA do inspections?

The Food and Drug Administration (FDA) conducts inspections and assessments of regulated facilities to determine a firm’s compliance with applicable laws and regulations, such as the Food, Drug, and Cosmetic Act and related Acts. Some inspection data may be not be posted until a final enforcement action is taken.

What is a pharmacovigilance inspection?

The focus of most European pharmacovigilance inspections is on the systems and processes in place to monitor drug safety, for products in pre- and post-marketing stages. The MHRA requires sponsor companies to complete a specific document called the ‘Summary of Pharmacovigilance Systems’ or SPS.

What is FDA inspected facility?

FDA inspects manufacturers or processors of Food and Drug Administration (FDA)-regulated products to verify that they comply with relevant regulations. Those inspected include: vaccine and drug manufacturers; • blood banks; • food processing facilities; • dairy farms; and • animal feed processors.

What are the types of FDA inspections?

The four different types of inspections conducted by FDA are pre-approval inspection, routine inspection, compliance follow-up inspection, and “for cause” inspection. Each is intended to help protect the public from unsafe products, but the focus and expectations of each type of inspection are different.

What are 3 types of inspection?

There are three primary types of quality inspections: pre-production, in-line, and final. There are a variety of details that must be inspected and approved during each phase in order to detect and correct quality problems.

What happens if you fail FDA inspection?

2. The FDA places an import alert on your products. The FDA might place an import alert on your products if your supplier fails to adequately respond to a warning letter. The FDA might also issue an import alert prior to sending the warning letter if the violations pose a serious health risk to consumers.

What is PV audit?

Pharmacovigilance (PV) Audits are designed to verify the appropriateness and effectiveness of the implementation and operation of a PV system, including its quality system.

What are the phases of inspection?

The stages in the inspections process are: Planning, Overview meeting, Preparation, Inspection meeting, Rework and Follow-up. The Preparation, Inspection meeting and Rework stages might be iterated.

How do you pass an FDA inspection?

Here are six ways to make sure you are:

  1. Make FDA Inspection Procedures Clear & Concise.
  2. Make Key Documents & Records Easily Accessible in an Inspection-Ready Binder.
  3. Label Items for Fast Retrieval.
  4. Compile Product Complaints & CAPAs Since Your Last Inspection.
  5. Report All Corrections/Recalls & Keep Documentation Current.

What happens after an FDA inspection?

After the inspection is complete, you’ll receive a letter from the FDA documenting the inspector’s findings. If regulatory deficiencies were found, they’ll be listed in the FDA form 483. In addition, the inspector will give a timetable or rough timeline by which any corrections should be made.

How are FDA warning letters related to pharmacovigilance?

Regulatory inspections are an everyday reality now, given the heightened level of scrutiny that the industry is facing from all the regulators. We at Sciformix recently conducted a DIA webinar on the topic of FDA warning letters in the context of Pharmacovigilance (PV) operations.

What do you need to know about pharmacovigilance practices in industry?

This document provides guidance to industry on good pharmacovigilance practices and pharmacoepidemiologic assessment of observational data regarding drugs, including biological drug products (excluding blood and blood components).

What to look for during an FDA inspection?

This is part of FDA’s Compliance Program Guidance Manual but is, in reality, more or less an SOP for FDA’s inspectors. Although there is nothing really new, it is worth reading to review what FDA will look for during an inspection of your company or a vendor handling drug safety and/PV.

When did FDA update postmarketing adverse drug experience guidance?

On December 15, 2012 FDA issued its updated Chapter 53 on Postmarketing Adverse Drug Experience (PADE) Reporting Instructions. This is part of FDA’s Compliance Program Guidance Manual but is, in reality, more or less an SOP for FDA’s inspectors.

Share this post